Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASSAN rem Spray (also known as ASSAN dolo rem spray or ASSA dolo rem spray) is an approved topical combination medication developed and manufactured by Permamed. It is formulated as a pump-dose spray for external use to treat localized pain, inflammation, and swelling associated with musculoskeletal injuries (such as sprains, bruises, and strains) and rheumatic complaints. The spray contains six active ingredients: hydroxyethyl salicylate (an NSAID that inhibits cyclooxygenase), dimethyl sulfoxide (DMSO, which acts as an anti-inflammatory agent and penetration enhancer), polidocanol 600 (a local anesthetic), dexpanthenol (a skin protectant), levomenthol, and racemic camphor (both acting as counterirritants and TRP channel modulators). It is designed to be non-greasy and does not stain skin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ASSAN rem Spray.